Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
about
Challenges of Pancreatic Cancer.Imaging in pancreatic disease.Molecular Imaging of Pancreatic Cancer with Antibodies.Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imagingp-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPETExtracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab(18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry.Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry.Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with 89Zr-5B1.Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models.Current status and future challenges for molecular imaging.Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
P2860
Q28080671-CB59348D-F40C-4BAA-AAA8-5294A7408E1AQ30275458-90F68238-3761-4578-9C78-AB91E8EDE8B2Q30393523-9EE84C85-297E-4584-821A-A05BE8101ED8Q33761754-EC246C93-1DED-4895-9E55-0AE0A4D73686Q34813272-1322189B-9957-40BE-9C00-ABDEC7A62993Q36435260-8C4C8350-179A-4460-BC1D-ED88CFBDE3BAQ36855892-384B35A2-B60C-4BBD-B453-5CC225632D64Q36944360-556D7F6C-AE24-4E58-BDF7-C527A5DF3318Q37129847-479AB7C2-F914-4878-ADB6-CE5BDA8BC4F1Q37708758-F246D39E-1B59-4FD1-B893-370C8E76CAF4Q38556842-A2AE7495-0BDE-47E4-B9EE-90C8AF236F1DQ38722557-D5CE3AF2-793A-45DE-9B77-4E69D8F64BA8Q38964406-1CCFAA5F-7FB0-43AD-BF2B-F9A87701BF7DQ47095216-4AC3689C-387F-42FE-990A-9ACCCB1AB1C0Q47646469-EABC51A6-FAC8-452C-95D8-66F777BACFBFQ52672665-1B6F06AB-1328-40AA-9482-8D5B4C81FE96Q55384914-11380E1B-95F4-41E7-9D49-15AEAAF4D365Q58699756-C1B35020-152E-4187-A629-081DAF7F43C4
P2860
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Applying PET to broaden the di ...... serum biomarker for oncology.
@ast
Applying PET to broaden the di ...... serum biomarker for oncology.
@en
Applying PET to broaden the di ...... serum biomarker for oncology.
@nl
type
label
Applying PET to broaden the di ...... serum biomarker for oncology.
@ast
Applying PET to broaden the di ...... serum biomarker for oncology.
@en
Applying PET to broaden the di ...... serum biomarker for oncology.
@nl
prefLabel
Applying PET to broaden the di ...... serum biomarker for oncology.
@ast
Applying PET to broaden the di ...... serum biomarker for oncology.
@en
Applying PET to broaden the di ...... serum biomarker for oncology.
@nl
P2093
P2860
P50
P1476
Applying PET to broaden the di ...... serum biomarker for oncology.
@en
P2093
Govind Ragupathi
Jason S Lewis
Kuntal K Sevak
Marija Drobjnak
Michael J Evans
Philip O Livingston
Ritsuko Sawada
Wolfgang W Scholz
Xiaohong Wu
P2860
P304
P356
10.2967/JNUMED.113.119867
P407
P577
2013-09-12T00:00:00Z